+49 30 838 62618
The efficacy of a dry cow treatment (DCT) with an internal teat seal (OrbeSeal) was evaluated in a controlled field study in a splitted udder design on a commercial dairy farm in Brandenburg, Germany.
The effect of an additional application of the non-antibiotic internal teal seal was quantified in comparison with an exclusive antibiotic dry cow therapy. Right front and left hind quarter or left front and right hind quarters respectively were treated with a combined dry cow treatment consisting of 1000 mg Cloxacillin (Orbenin extra, Pfizer)
and a non-antibiotic teat seal (Bismuthsubnitrat, Orbeseal, Pfizer, treatment quarters) while the other two remaining quarters of the study animals were treated with an antibiotic dry cow treatment consisting of Cloxacillin (Orbenin extra, Pfizer, control quarters). In total 359 animals (1436 quarters) were enrolled. Regarding the
development of the somatic cell count there were no differences between the treatment and the control group. The prevalence of IMI at calving and 5–8 days after calving was lower in the combined treated quarters than in the antibiotically treated control quarters. The
combined treated quarters developed fewer intramammary infections in the three periods of analysis (dry off until calving: 7.5% vs 10.3%, dry off until 5–8 days post-calving: 10.3% vs 14.3%, calving until 5–8 days post- calving: 10.4% vs 13.0%) compared to the antibiotically treated quarters. The combined treated quarters showed a lower
incidence of clinical mastitis than the antibiotic treated quarters (92 quarters vs 99 quarters). In quarters with risk factors (high milk yield at the dry off and teat duct hyperceratosis) the reduction of incidence of new IMI because of the combined therapy compared to the antibiotic DCT was higher. Furthermore the results of our study
indicate that the combined therapy causes no irritation of the mammary gland.